Skip to main content
Journal cover image

Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor

Publication ,  Journal Article
Becker, RC; Chan, MY; Vavalle, JP; Povsic, TJ
Published in: Drug Development Research
December 1, 2013

Clinical Development Phases I-III Regulatory, Quality, Manufacturing Thrombosis as a clinical phenotype is ubiquitous in human diseases and conditions, ranging from atherosclerosis and other vascular disorders to trauma, surgery, malignancy, infections, blood dyscrasias, auto-immunity, and complications of pregnancy. While each condition carries its own distinct signature and predisposition for thrombosis as a nonphysiological event, there are several common themes that center on cellular and noncellular elements, including well-characterized coagulation proteases. Over the past decade, our group has been actively involved with the development of a factor IXa inhibitor, pegnivacogin, and its complementary antidote or control agent, anivamersen. The following review provides a summary of fundamental constructs, milestones, and the current status of our translational journey. © 2013 Wiley Periodicals, Inc.

Duke Scholars

Published In

Drug Development Research

DOI

EISSN

1098-2299

ISSN

0272-4391

Publication Date

December 1, 2013

Volume

74

Issue

8

Start / End Page

510 / 516

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Becker, R. C., Chan, M. Y., Vavalle, J. P., & Povsic, T. J. (2013). Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor. Drug Development Research, 74(8), 510–516. https://doi.org/10.1002/ddr.21109
Becker, R. C., M. Y. Chan, J. P. Vavalle, and T. J. Povsic. “Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor.” Drug Development Research 74, no. 8 (December 1, 2013): 510–16. https://doi.org/10.1002/ddr.21109.
Becker RC, Chan MY, Vavalle JP, Povsic TJ. Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor. Drug Development Research. 2013 Dec 1;74(8):510–6.
Becker, R. C., et al. “Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor.” Drug Development Research, vol. 74, no. 8, Dec. 2013, pp. 510–16. Scopus, doi:10.1002/ddr.21109.
Becker RC, Chan MY, Vavalle JP, Povsic TJ. Anticoagulation and monitoring of a novel and reversible factor IXa inhibitor. Drug Development Research. 2013 Dec 1;74(8):510–516.
Journal cover image

Published In

Drug Development Research

DOI

EISSN

1098-2299

ISSN

0272-4391

Publication Date

December 1, 2013

Volume

74

Issue

8

Start / End Page

510 / 516

Related Subject Headings

  • Pharmacology & Pharmacy
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences